Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration-resistant Prostate Cancer (mCRPC)”

422 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 422 results

Testing effectiveness (Phase 2)Looking for participantsNCT06971211
What this trial is testing

Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Jianbin Bi 40
Large-scale testing (Phase 3)Looking for participantsNCT03903835
What this trial is testing

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet 750
Not applicableStudy completedNCT03563014
What this trial is testing

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Bayer 164
Early research (Phase 1)Not Yet RecruitingNCT06866795
What this trial is testing

Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Geode Therapeutics Inc. 42
Early research (Phase 1)Study completedNCT02215096
What this trial is testing

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 37
Not applicableStudy completedNCT02471469
What this trial is testing

Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Radboud University Medical Center 40
Very early researchStudy completedNCT05725070
What this trial is testing

Phase 0/1 Study of 212Pb-NG001 in mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
ARTBIO Inc. 3
Early research (Phase 1)Looking for participantsNCT05942001
What this trial is testing

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 100
Early research (Phase 1)Active Not RecruitingNCT06229366
What this trial is testing

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more
Eli Lilly and Company 142
Testing effectiveness (Phase 2)Study completedNCT03643107
What this trial is testing

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer Patients
Allarity Therapeutics 15
Testing effectiveness (Phase 2)Ended earlyNCT03741712
What this trial is testing

SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 9
Not applicableStudy completedNCT03176381
What this trial is testing

Tissue Predictors of Abiraterone Benefit

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Tianjin Medical University Second Hospital 110
Large-scale testing (Phase 3)Active Not RecruitingNCT05348577
What this trial is testing

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
AstraZeneca 1,035
Testing effectiveness (Phase 2)Ended earlyNCT04631744
What this trial is testing

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 4
Testing effectiveness (Phase 2)Study completedNCT02020135
What this trial is testing

An Open-label Extension Study of PSMA ADC 2301 in mCRPC

Who this might be right for
Prostate Cancer
Progenics Pharmaceuticals, Inc. 9
Large-scale testing (Phase 3)Study completedNCT03834506
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Who this might be right for
Prostatic Neoplasms
Merck Sharp & Dohme LLC 1,030
Early research (Phase 1)Looking for participantsNCT06826768
What this trial is testing

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center 60
Not applicableStudy completedNCT03223597
What this trial is testing

Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 300
Testing effectiveness (Phase 2)Study completedNCT03939689
What this trial is testing

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

Who this might be right for
Metastatic Prostate CancerCastration-resistant Prostate CancerProstatic Neoplasm+2 more
Progenics Pharmaceuticals, Inc. 120
Early research (Phase 1)Ended earlyNCT05369000
What this trial is testing

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Lava Therapeutics 96
Next Page